New Jersey program helps life sciences therapeutics companies commercialize.
PRINCETON, NEW JERSEY (March 20, 2024) — Inaedis, Inc., new platform biotechnology company, was awarded $150,000 in non-dilutive funding from the Catalyst Seed R&D Grant Program, a state-led initiative to support deep biotechnology ventures in New Jersey.
Catalyst is led by the New Jersey Commission on Science, Innovation and Technology. Catalyst’s mission is to help early stage innovation-based companies accelerate development of technologies to transform new discoveries from research into commercially viable products and services.
The award from Catalyst will enable Inaedis to continue developing its proprietary Rapid Room-Temperature Dehydration (RTAD) platform technology at the Princeton Innovation Center Biolabs.
“New Jersey has always been at the forefront of innovation with institutions like Bell Labs, Princeton University, the Institute for Advanced Study, and more,” said Dr. Maksim Mezhericher, Inaedis Founder and CEO. “It’s one of the best educated, hardest working states in America. We’re proud to call New Jersey home.”
RTAD finally solves the global dilemma posed by the thermal stabilization requirements of life-saving heat and freeze-sensitive vaccines and biologics. Validated in a recent joint study with a top 10 pharmaceutical company in the Journal of Pharmaceutical Sciences, RTAD has the capacity to transform vaccine development, delivery, and distribution.
Inaedis, Inc.
Inaedis, Inc. is a spin-out company from Princeton University developing a pharmaceutical platform changing the future of drug development, delivery, and distribution by powderizing life-saving vaccines and biologics.
First developed by Princeton scientists during the Covid-19 pandemic, our goal is to give everyone access to the miracles of modern medicine. Our proprietary Rapid Room-Temperature Dehydration (RTAD) platform technology finally solves the global dilemma posed by the thermal stabilization requirements of life-saving heat and freeze-sensitive vaccines and biologics.
Inaedis is led by its founders: CEO Dr. Maksim Mezhericher and Prof. Howard A. Stone and is backed by Roadrunner Venture Studios and Princeton Innovation Center.
Media Contact: Maksim Mezhericher, maksim@inaedis.com